GRADE 3A FOLLICULAR LYMPHOMA

This study is for people with a slow-growing type of blood cancer called follicular lymphoma that has come back or stopped responding to treatment. Researchers are testing whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults w…

This study tests a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) in 40 people with untreated follicular lymphoma, a slow-growing blood cancer. The goal is to see if the combination works better than each drug alone at shrinking tumors and controlling the di…

This study tests a combination of two drugs—nivolumab and lenalidomide—in people with non-Hodgkin or Hodgkin lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see how well the drugs work together. About 36 adults with specific …

This early-phase study tests whether adding the drug acalabrutinib to a type of immune cell therapy (CAR T-cells) can safely treat B-cell lymphoma, a cancer of the immune system. About 23 adults with certain aggressive or slow-growing lymphomas will receive the combination. The g…

This study tests a combination of three drugs (acalabrutinib, lenalidomide, and rituximab) in 60 people with advanced follicular lymphoma who have not had treatment before. The goal is to see how well the drugs work together to shrink or eliminate cancer. Participants take the dr…

This early-phase study tests a combination of three drugs (obinutuzumab, venetoclax, and lenalidomide) in 22 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and see if the combination can shri…

This study tests a combination of two drugs, obinutuzumab and ibrutinib, as the first treatment for people with slow-growing non-Hodgkin's lymphoma. The goal is to see how well the drugs shrink or eliminate cancer. About 30 adults with newly diagnosed lymphoma will receive this t…

This study tests a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. The drug works by blocking certain enzymes that help cancer cells grow. The main goal is to see how many patients have their tumors shrink or disappe…